Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Odense, Denmark.
Radiother Oncol. 2024 Nov;200:110481. doi: 10.1016/j.radonc.2024.110481. Epub 2024 Aug 17.
Rib fracture is a known complication after stereotactic body radiotherapy (SBRT). Patient-related parameters are essential to provide patient-tailored risk estimation, however, their impact on rib fracture is less documented compared to dosimetric parameters. This study aimed to predict the risk of rib fractures in patients with localized non-small cell lung cancer (NSCLC) post-SBRT based on both patient-related and dosimetric parameters with death as a competing risk.
In total, 602 patients with localized NSCLC treated with SBRT between 2010-2020 at Odense University Hospital, Denmark were included. All patients received SBRT with 45-66 Gray (Gy)/3 fractions. Rib fractures were identified in CT-scans using a word embedding model. The cumulative incidence function was based on cause-specific Cox hazard models with variable selection based on cross-validation model likelihood performed using 50 bootstraps.
In total, 19 % of patients experienced a rib fracture. The cumulative risk of rib fracture increased rapidly from 6-54 months post-SBRT. Female gender, bone density, near max dose to the rib, V30 and V40 to the rib, gross tumor volume, and mean lung dose were significantly associated with rib fracture risk in univariable analysis. The final multi-variable model consisted of V20 and V30 to the rib and mean lung dose.
Female gender and low bone density in male patients are significant predictors of rib fracture risk. The final model predicting cumulative rib fracture risk of 19 % in patients with localized NSCLC treated with SBRT contained no patient-related parameters, suggesting that dosimetric parameters are the primary drivers.
立体定向体部放疗(SBRT)后发生肋骨骨折是已知的并发症。患者相关参数对于提供针对患者的风险评估至关重要,但是与剂量学参数相比,其对肋骨骨折的影响记录较少。本研究旨在基于患者相关和剂量学参数,预测局部非小细胞肺癌(NSCLC)患者 SBRT 后发生肋骨骨折的风险,并以死亡为竞争风险。
共纳入 2010 年至 2020 年期间在丹麦欧登塞大学医院接受 SBRT 治疗的 602 例局部 NSCLC 患者。所有患者均接受 45-66 Gray(Gy)/3 个分次的 SBRT。使用词嵌入模型在 CT 扫描中识别肋骨骨折。累积发生率函数基于基于特定原因的 Cox 风险模型,使用 50 个自举法进行交叉验证模型似然的变量选择。
共有 19%的患者发生了肋骨骨折。SBRT 后 6-54 个月时,肋骨骨折的累积风险迅速增加。女性、骨密度、肋骨附近最大剂量、V30 和 V40 到肋骨、大体肿瘤体积和平均肺剂量在单变量分析中与肋骨骨折风险显著相关。最终的多变量模型包括肋骨的 V20 和 V30 以及平均肺剂量。
女性和男性患者的低骨密度是肋骨骨折风险的显著预测因素。预测接受 SBRT 治疗的局部 NSCLC 患者累积肋骨骨折风险为 19%的最终模型不包含患者相关参数,表明剂量学参数是主要驱动因素。